FNArena Windows

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

Cochlear is raising equity to preserve liquidity, placing the business on the front foot for a recovery once the deferral of non-essential surgery has passed.

Mar 26 2020

Cochlear has withdrawn FY20 guidance and expects the subsequent recovery in implant surgery will be slow.

Mar 17 2020


ASX CODE LAST PRICE % MOVE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET UPSIDE/DOWNSIDE
CAT $0.87 0.00% $2.24 $0.50

$1.68

93.1%

COH $185.30

-3.17%

$254.40 $154.60 75.0

$176.329

-4.8%

FPH $26.58

-7.10%

$31.47 $14.00 62.9

IDX $2.50

-0.79%

$4.39 $1.78 15.7

$4.316

72.6%

IPD $0.04 0.00% $0.35 $0.03

$0.26

550.0%

MX1 $0.14

7.69%

$0.39 $0.11

$0.41

192.9%

NAN $6.01

0.17%

$7.73 $4.01 154.5

$6.273

4.4%

PME $22.76

6.55%

$38.39 $14.50 97.1

$30.24

32.9%

RAP $0.19

-5.00%

$0.42 $0.06

$0.24

26.3%

RMD $25.19

-2.93%

$26.66 $13.56 42.0

$23.315

-7.4%

SOM $1.02

12.09%

$3.44 $0.90

$1.33

30.4%

VHT $1.21

4.31%

$2.17 $0.00

$1.68

38.8%

Previous Stories
Pro Medicus Moving On New Revenue Streams

Feb 18 2020

Pro Medicus continues to invest heavily in R&D and, over the next 2-3 years, should generate revenue from new areas such as ophthalmology and cardiology.


Confidence In ResMed Continues Unabated

Feb 03 2020

Sleep therapy business ResMed expanded its product portfolio and took market share in the first half. Most brokers are confident growth will remain robust over the balance of FY20.


Fisher & Paykel Healthcare Too Pricey?

Nov 29 2019

Fisher & Paykel Healthcare experienced a jump in device sales during the first half but brokers remain concerned about the high price of the stock.


Will ResMed’s Growth Rates Taper?

Oct 28 2019

While ResMed has recovered its lead in the sleep disorder market, several brokers suspect stellar growth rates may taper.


RESEARCH: Innovative Medical Device Company, Imagion Biosystems

Sep 27 2019

Pitt Street Research explains why Imagion Biosystems shares look undervalued.


Nanosonics On The Move

Jul 30 2019

Michael Gable of Fairmont Equities suggests Nanosonics should continue higher from here.


Connected Care Working Well For ResMed

Jul 29 2019

After a strong FY19, sleep apnoea specialist ResMed is expected to make further inroads into market share in FY20 with its “connected-care” strategy.


F&P Healthcare Needs To Lift Mask Growth

May 28 2019

Fisher & Paykel Healthcare requires a significant improvement in its OSA mask performance as well as high growth rates in new hospital applications to meet targets, brokers assess.


ResMed Gains Share In Core Sleep Market

May 06 2019

Sleep apnoea revenue partly offset weaker software-as-a-service revenue in the March quarter for ResMed, which is gaining share from the strong uptake of new products.


Cochlear’s New Implant Should Restore Share

Apr 17 2019

Cochlear has launched its MRI-compatible implant but brokers do not expect the new product will impact revenue and market share until FY20.